Journal article
Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage
AR Parry-Jones, M Di Napoli, JN Goldstein, FHBM Schreuder, S Tetri, T Tatlisumak, B Yan, KM Van Nieuwenhuizen, N Dequatre-Ponchelle, M Lee-Archer, S Horstmann, D Wilson, F Pomero, L Masotti, C Lerpiniere, DA Godoy, AS Cohen, R Houben, R Al-Shahi Salman, P Pennati Show all
Annals of Neurology | Published : 2015
DOI: 10.1002/ana.24416
Abstract
Objective There is little evidence to guide treatment strategies for intracerebral hemorrhage on vitamin K antagonists (VKA-ICH). Treatments utilized in clinical practice include fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC). Our aim was to compare case fatality with different reversal strategies. Methods We pooled individual ICH patient data from 16 stroke registries in 9 countries (n=10 282) of whom 1,797 (17%) were on VKA. After excluding 250 patients with international normalized ratio<1.3 and/or missing data required for analysis, we compared all-cause 30-day case fatality using Cox regression. Results We included 1,547 patients treated with FFP (n=377, 24%) PCC (n..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This study was supported by the University of Manchester (A.R.P.-J.), the Salford Royal NHS Foundation Trust (A.R.P.-J.), the Academy of Medical Sciences (A.R.P.-J.), the Dowager Countess Eleanor Peel Trust (A.R.P.-J.), the Natalie Kate Moss Trust (A.R.P.-J.), the Italian National Health Service (M.D.N.), a grant from the Helsinki University Central Hospital for research on intracerebral hemorrhage (T.T.), a clinical established investigator grant from the Dutch Heart Foundation (2012T077, C.J.M.K.), an ASPASIA grant from the Netherlands Organization for Health Research and Development (015008048, C.J.M.K.), the Finnish Brain Foundation (J.H.), the Finnish Medical Foundation (J.H., A.M.), the NIH National Institute of Neurological Disorders and Stroke (R01 NS059727, J.R.), the Academy of Finland (A.M.), and the National Health and Medical Research Council (Australia; A.M.). CROMIS-2 was funded by a grant from the British Heart Foundation and the Stroke Association (UK; chief investigator: D.We.). LATCH was funded by an MRC senior clinical fellowship (R.A.-S.S.) and an MRC/Stroke Association clinical research training fellowship.